Blog

We’re Excited to Announce That the First Patient Has Been Randomised in the PROLoNG Study – EORTC

EORTC/LinkedIn

Jul 10, 2025, 20:44

We’re Excited to Announce That the First Patient Has Been Randomised in the PROLoNG Study – EORTC

EORTC – European Organisation for Research and Treatment of Cancer shared on LinkedIn:

“We’re excited to announce that the first patient has been randomised in the PROLoNG study!

The patient was enrolled at Hospital Universitari Vall d’Hebron, under the supervision of Principal Investigator Irene Braña.

The EORTC-2014 PROLoNg study focuses on Pembrolizumab and Radiotherapy for OLigometastatic squamous cell carcinoma of the head and Neck: a randomised phase III study.

Two Spanish sites are currently active in this international trial, with more to follow soon.
Learn more.

The PROLoNg study is supported by MSD,

Spanish Association Against Cancer, EORTC Cancer Research Fund, and Belgian Foundation Against Cancer.”

More posts featuring EORTC.

Cancer research clinical trials EORTC European Organisation for Research and Treatment of Cancer Hospital Universitari Vall d’Hebron Irene Brana PROLoNG study

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers